EAST FALMOUTH, Mass., March 17 /PRNewswire/ -- Associates of Cape Cod, Inc. (ACC), a leading manufacturer of endotoxin and beta-glucan detection products and a major supplier to the pharmaceutical and medical device industries, today announced that Dr. A.J. Meuse has joined the Company as president and chief executive officer, effective immediately.
(Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040317/NEW022 )
Dr. Meuse is a proven executive with over 15 years experience in the medical device and life science sectors. His experience includes positions as Chief Operating Officer, Executive Vice President, Senior New Project Program Manager and Worldwide Product Marketing Manager with technology focused companies ranging from start-ups to large corporations.
Most recently, Dr. Meuse was executive vice president of North American Scientific's Biotechnology Business Unit, Theseus Imaging Corporation. He previously held product development and business management positions at Bausch & Lomb and Corning-Costar Life Science and was Chief Operating Officer of Molecular Geodesics and Cytomatrix. Dr. Meuse was also a consultant to top-tier pharmaceutical, biopharmaceutical and medical device companies and a Manager of a technology oriented product development consulting firm.
"With the addition of A.J. Meuse, Associates of Cape Cod gains an accomplished, results-oriented CEO with proven business management and technical expertise," said ACC's Chairman, Keiji Takahashi. "The Company is poised for growth and we are pleased to welcome A.J. to the organization at this time."
Dr. Meuse has an M.B.A. from the University of New Hampshire's Whittemore School of Business and Economics, and a Ph.D. in Biomedical Science from Worcester Polytechnic Institute and the University of Massachusetts School of Medicine consortium doctoral program.
About Associates of Cape Cod, Inc.
Associates of Cape Cod, Inc., based in Falmouth, MA, is a leader in the field of bacterial endotoxin and beta-glucan detection. A wholly owned subsidiary of Seikagaku Corporation, the Company pioneered the use of Horseshoe Crab blood extract, Limulus Amebocyte Lysate (LAL), used in the testing of pharmaceuticals, medical devices and biologics, for the presence of potentially toxic endotoxins and glucans. In 1977 the Company was the first to receive an FDA license for the manufacture of this reagent. Our products are marketed throughout the world under the trade names Pyrotell(R), Glucatell(R), Pyrochrome(R) and Chromo-LAL. The Company also offers contract testing for endotoxins and glucans, and has a research biochemicals division, Seikagaku America, specializing in carbohydrate chemistry. For more information about Associates of Cape Cod, Inc. and our products, please visit our website at: http://www.acciusa.com/.
Media Contact: Amy B. Tarbox press@acciusa.com Company Contact: Debbie Fraser 508-540-3808 ext. 2228
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040317/NEW022AP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comAssociates of Cape Cod, Inc.CONTACT: Media, Amy B. Tarbox, press@acciusa.com, or Company, DebbieFraser, +1-508-540-3808 ext. 2228, both of Associates of Cape Cod, Inc.
Web site: http://www.acciusa.com/
